Metropolis Healthcare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹497 Cr +15.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
MH

Metropolis Healthcare Ltd

Q4 FY26Healthcare Services

Metropolis Healthcare Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹425Cr
+23.2% YoY
+4.7% QoQ
Net profit
₹51Cr
+75.9% YoY
+21.4% QoQ
Margin
25%
+7 pp YoY
+2 pp QoQ
Price₹557
Market cap₹11.3K Cr
P/E54.4

The short version

Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years. Metropolis Healthcare projects a revenue CAGR of 14% to 15% over the next 3 years driven by patient volume growth, realization improvement, and strategic acquisitions.

From Metropolis Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years.
  • Volume Growth: Patient volume growth is forecasted at about 8% to 9% for the coming fiscal, contributing significantly to overall growth.
  • Realization/Price Growth: Approximately 5% of growth is expected from better price realization driven by specialty and core diagnostics.
  • Digital Channels: Digital revenue has grown to 25% and is expected to further drive volume and margin expansion.
  • Network Expansion: Focus on enhancing productivity of existing centers by 20% over 3 years and adding 1,500 new collection centers to improve the lab-to-center ratio from 1:24 to 1:35.

2 more points from Metropolis Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Metropolis Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY26 capex stood at INR 65 crores, focused on targeted network addition, specialty test expansion, technology upgrades, and digital capabilities.
  • Future investments will be increasingly selective and productivity-driven.
  • Plan to build around 100 mini hubs over the next 3 years, combining pathology and basic radiology services for retail and corporate clients.
  • Mini hubs capex estimated at INR 30-40 lakhs each, higher than collection centers but similar to satellite labs.
  • Expansion of the asset-light collection center network by adding 1,500 more centers, improving the lab-to-center ratio from 1:24 to 1:35.
  • Emphasis on technology enablement and automation to drive center productivity and margin expansion.

2 more points from Metropolis Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Metropolis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Metropolis Healthcare Ltd said on order book & pipeline — free account, 30 seconds.

Metropolis Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Metropolis Healthcare Ltd Q4 FY26 results — key figures

Metropolis Healthcare Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue425345+23.2%406+4.7%
Operating profit (EBITDA)10862+74.2%95+13.7%
Operating margin25%18%+7 pp23%+2 pp
Profit before tax7036+94.4%57+22.8%
Net profit (PAT)5129+75.9%42+21.4%
EPS (₹)2.461.41+74.5%2.00+23%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹497 Cr, net profit ₹75 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Metropolis Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Metropolis Healthcare Ltd Q4 FY26 results?

Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years. Metropolis Healthcare projects a revenue CAGR of 14% to 15% over the next 3 years driven by patient volume growth, realization improvement, and strategic acquisitions.

What is Metropolis Healthcare Ltd share price analysis?

Metropolis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.4 with a market cap of ₹11,313 Cr. Investors should review the full earnings analysis for detailed insights.

Is Metropolis Healthcare Ltd planning capital expenditure?

FY26 capex stood at INR 65 crores, focused on targeted network addition, specialty test expansion, technology upgrades, and digital capabilities.

Keep Metropolis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.